DPP4 and Hypertension: Sixth, the HR and 95% CI of developing hypertension in SGLT2i users was 0.93 (0.86–1.01) compared to that in DPP4 inhibitor users after excluding individuals who had any antidiabetic medications at the index date (Supplementary Table 6).